Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults

Detalhes bibliográficos
Autor(a) principal: Menzies, Dick
Data de Publicação: 2018
Outros Autores: Adjobimey, Menonli, Ruslami, Rovina, Trajman, Anete, Sow, Oumou, Kim, Heejin, Obeng Baah, Joseph, Marks, Guy B., Long, Richard, Hoeppner, Vernon, Elwood, Kevin, Al-Jahdali, Hamdan, Gninafon, Martin, Apriani, Lika, Koesoemadinata, Raspati C., Kritski, Afranio, Rolla, Valeria, Bah, Boubacar, Camara, Alioune, Boakye, Isaac, Cook, Victoria J., Goldberg, Hazel, Valiquette, Chantal, Hornby, Karen, Dion, Marie-Josée, Li, Pei-Zhi, Hill, Philip C., Schwartzman, Kevin, Benedetti, Andrea
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/33753
Resumo: Valéria Rolla. Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta a informação no documento. Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University Health Centre Research Institute (D.M., A.T., C.V., K.H., M.-J.D., P.Z.L., K.S., A.B.), and the Department of Epidemiology and Biostatistics (D.M., A.B.), McGill University, Montreal, the Faculty of Medicine and Dentistry, University of Alberta, Edmonton (R.L.), the Faculty of Medicine, University of Saskatchewan, Saskatoon (V.H.), and the BC Centre for Disease Control and the University of British Columbia, Vancouver (K.E., V.J.C.) — all in Canada; Centre National Hospitalier Universitaire de Pneumo-Phtisiologie, Cotonou, Benin (M.A., M.G.); the Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia (R.R., L.A., R.C.K.); State University of Rio de Janeiro (A.T.), Programa Academico de Tuberculose–Faculdade de Medicina, Universidade Federal do Rio de Janeiro–Rede TB (A.K.), and National Institute of Infectious Diseases Evandro Chagas (V.R.) — all in Rio de Janeiro; Service de Pneumophtisiologie, Hôpital National Ignace Deen, Université Gamal Abdel Nasser de Conakry, Conakry, Guinea (O.S., B.B., A.C.); Korean Institute of Tuberculosis, Seoul, South Korea (H.K.); Komfo Anokye Teaching Hospital, Kumasi, Ghana (J.O.B., I.B.); University of New South Wales (G.B.M.) and University of Sydney (H.G.), Sydney; Centre for International Health, University of Otago, Dunedin, New Zealand (P.C.H.); and the Department of Medicine, King Saud University, King Abdulaziz Medical City, Riyadh, Saudi Arabia (H.A.-J.).
id CRUZ_a114fe568fd51a65e02947708441c72f
oai_identifier_str oai:www.arca.fiocruz.br:icict/33753
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Menzies, DickAdjobimey, MenonliRuslami, RovinaTrajman, AneteSow, OumouKim, HeejinObeng Baah, JosephMarks, Guy B.Long, RichardHoeppner, VernonElwood, KevinAl-Jahdali, HamdanGninafon, MartinApriani, LikaKoesoemadinata, Raspati C.Kritski, AfranioRolla, ValeriaBah, BoubacarCamara, AliouneBoakye, IsaacCook, Victoria J.Goldberg, HazelValiquette, ChantalHornby, KarenDion, Marie-JoséeLi, Pei-ZhiHill, Philip C.Schwartzman, KevinBenedetti, Andrea2019-07-01T14:39:44Z2019-07-01T14:39:44Z2018MENZIES, D. et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. New England Journal of Medicine, v. 379, n. 5, p. 440-453, Aug. 2 2018.0028-4793https://www.arca.fiocruz.br/handle/icict/3375310.1056/NEJMoa17142831533-4406Valéria Rolla. Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta a informação no documento. Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University Health Centre Research Institute (D.M., A.T., C.V., K.H., M.-J.D., P.Z.L., K.S., A.B.), and the Department of Epidemiology and Biostatistics (D.M., A.B.), McGill University, Montreal, the Faculty of Medicine and Dentistry, University of Alberta, Edmonton (R.L.), the Faculty of Medicine, University of Saskatchewan, Saskatoon (V.H.), and the BC Centre for Disease Control and the University of British Columbia, Vancouver (K.E., V.J.C.) — all in Canada; Centre National Hospitalier Universitaire de Pneumo-Phtisiologie, Cotonou, Benin (M.A., M.G.); the Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia (R.R., L.A., R.C.K.); State University of Rio de Janeiro (A.T.), Programa Academico de Tuberculose–Faculdade de Medicina, Universidade Federal do Rio de Janeiro–Rede TB (A.K.), and National Institute of Infectious Diseases Evandro Chagas (V.R.) — all in Rio de Janeiro; Service de Pneumophtisiologie, Hôpital National Ignace Deen, Université Gamal Abdel Nasser de Conakry, Conakry, Guinea (O.S., B.B., A.C.); Korean Institute of Tuberculosis, Seoul, South Korea (H.K.); Komfo Anokye Teaching Hospital, Kumasi, Ghana (J.O.B., I.B.); University of New South Wales (G.B.M.) and University of Sydney (H.G.), Sydney; Centre for International Health, University of Otago, Dunedin, New Zealand (P.C.H.); and the Department of Medicine, King Saud University, King Abdulaziz Medical City, Riyadh, Saudi Arabia (H.A.-J.).2020-01-01Múltipla - Ver em Notas.BACKGROUND: A 9-month regimen of isoniazid can prevent active tuberculosis in persons with latent tuberculosis infection. However, the regimen has been associated with poor adherence rates and with toxic effects. METHODS: In an open-label trial conducted in nine countries, we randomly assigned adults with latent tuberculosis infection to receive treatment with a 4-month regimen of rifampin or a 9-month regimen of isoniazid for the prevention of confirmed active tuberculosis within 28 months after randomization. Noninferiority and potential superiority were assessed. Secondary outcomes included clinically diagnosed active tuberculosis, adverse events of grades 3 to 5, and completion of the treatment regimen. Outcomes were adjudicated by independent review panels. RESULTS: Among the 3443 patients in the rifampin group, confirmed active tuberculosis developed in 4 and clinically diagnosed active tuberculosis developed in 4 during 7732 person-years of follow-up, as compared with 4 and 5 patients, respectively, among 3416 patients in the isoniazid group during 7652 person-years of follow-up. The rate differences (rifampin minus isoniazid) were less than 0.01 cases per 100 person-years (95% confidence interval [CI], −0.14 to 0.16) for confirmed active tuberculosis and less than 0.01 cases per 100 person-years (95% CI, −0.23 to 0.22) for confirmed or clinically diagnosed tuberculosis. The upper boundaries of the 95% confidence interval for the rate differences of the confirmed cases and for the confirmed or clinically diagnosed cases of tuberculosis were less than the prespecified noninferiority margin of 0.75 percentage points in cumulative incidence; the rifampin regimen was not superior to the isoniazid regimen. The difference in the treatment-completion rates was 15.1 percentage points (95% CI, 12.7 to 17.4). The rate differences for adverse events of grade 3 to 5 occurring within 146 days (120% of the 4-month planned duration of the rifampin regimen) were −1.1 percentage points (95% CI, −1.9 to −0.4) for all events and −1.2 percentage points (95% CI, −1.7 to −0.7) for hepatotoxic events. CONCLUSIONS: The 4-month regimen of rifampin was not inferior to the 9-month regimen of isoniazid for the prevention of active tuberculosis and was associated with a higher rate of treatment completion and better safety.engMassachusetts Medical SocietyFour months of rifampin or nine months of isoniazid for latent tuberculosis in adultsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleTuberculosisLatent tuberculosis in adultsRifampinIsoniazidinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-83104https://www.arca.fiocruz.br/bitstream/icict/33753/1/license.txt79178e5f2a0eb066867a274556814938MD51ORIGINALve_Menzies_D_etal_INI_2018.pdfve_Menzies_D_etal_INI_2018.pdfapplication/pdf276833https://www.arca.fiocruz.br/bitstream/icict/33753/2/ve_Menzies_D_etal_INI_2018.pdfd2a7963ffbac51b784b6286cad028272MD52TEXTve_Menzies_D_etal_INI_2018.pdf.txtve_Menzies_D_etal_INI_2018.pdf.txtExtracted texttext/plain67387https://www.arca.fiocruz.br/bitstream/icict/33753/3/ve_Menzies_D_etal_INI_2018.pdf.txta3bb7dfb0f4e60de467eb1e06af5df8fMD53icict/337532021-03-24 16:32:27.034oai:www.arca.fiocruz.br:icict/33753Q0VTU8ODTyBOw4NPIEVYQ0xVU0lWQSBERSBESVJFSVRPUyBBVVRPUkFJUw0KDQpKYW5hw61uYSBOYXNjaW1lbnRvLCBDUEY6IDAxNC41MDkuNTI3LTQ3LCB2aW5jdWxhZG8gYSBJTkkgLSBJbnN0aXR1dG8gTmFjaW9uYWwgZGUgSW5mZWN0b2xvZ2lhIEV2YW5kcm8gQ2hhZ2FzCgpBbyBhY2VpdGFyIG9zIFRFUk1PUyBlIENPTkRJw4fDlUVTIGRlc3RhIENFU1PDg08sIG8gQVVUT1IgZS9vdSBUSVRVTEFSIGRlIGRpcmVpdG9zCmF1dG9yYWlzIHNvYnJlIGEgT0JSQSBkZSBxdWUgdHJhdGEgZXN0ZSBkb2N1bWVudG86CgooMSkgQ0VERSBlIFRSQU5TRkVSRSwgdG90YWwgZSBncmF0dWl0YW1lbnRlLCDDoCBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVosIGVtCmNhcsOhdGVyIHBlcm1hbmVudGUsIGlycmV2b2fDoXZlbCBlIE7Dg08gRVhDTFVTSVZPLCB0b2RvcyBvcyBkaXJlaXRvcyBwYXRyaW1vbmlhaXMgTsODTwpDT01FUkNJQUlTIGRlIHV0aWxpemHDp8OjbyBkYSBPQlJBIGFydMOtc3RpY2EgZS9vdSBjaWVudMOtZmljYSBpbmRpY2FkYSBhY2ltYSwgaW5jbHVzaXZlIG9zIGRpcmVpdG9zCmRlIHZveiBlIGltYWdlbSB2aW5jdWxhZG9zIMOgIE9CUkEsIGR1cmFudGUgdG9kbyBvIHByYXpvIGRlIGR1cmHDp8OjbyBkb3MgZGlyZWl0b3MgYXV0b3JhaXMsIGVtCnF1YWxxdWVyIGlkaW9tYSBlIGVtIHRvZG9zIG9zIHBhw61zZXM7CgooMikgQUNFSVRBIHF1ZSBhIGNlc3PDo28gdG90YWwgbsOjbyBleGNsdXNpdmEsIHBlcm1hbmVudGUgZSBpcnJldm9nw6F2ZWwgZG9zIGRpcmVpdG9zIGF1dG9yYWlzCnBhdHJpbW9uaWFpcyBuw6NvIGNvbWVyY2lhaXMgZGUgdXRpbGl6YcOnw6NvIGRlIHF1ZSB0cmF0YSBlc3RlIGRvY3VtZW50byBpbmNsdWksIGV4ZW1wbGlmaWNhdGl2YW1lbnRlLApvcyBkaXJlaXRvcyBkZSBkaXNwb25pYmlsaXphw6fDo28gZSBjb211bmljYcOnw6NvIHDDumJsaWNhIGRhIE9CUkEsIGVtIHF1YWxxdWVyIG1laW8gb3UgdmXDrWN1bG8sCmluY2x1c2l2ZSBlbSBSZXBvc2l0w7NyaW9zIERpZ2l0YWlzLCBiZW0gY29tbyBvcyBkaXJlaXRvcyBkZSByZXByb2R1w6fDo28sIGV4aWJpw6fDo28sIGV4ZWN1w6fDo28sCmRlY2xhbWHDp8OjbywgcmVjaXRhw6fDo28sIGV4cG9zacOnw6NvLCBhcnF1aXZhbWVudG8sIGluY2x1c8OjbyBlbSBiYW5jbyBkZSBkYWRvcywgcHJlc2VydmHDp8OjbywgZGlmdXPDo28sCmRpc3RyaWJ1acOnw6NvLCBkaXZ1bGdhw6fDo28sIGVtcHLDqXN0aW1vLCB0cmFkdcOnw6NvLCBkdWJsYWdlbSwgbGVnZW5kYWdlbSwgaW5jbHVzw6NvIGVtIG5vdmFzIG9icmFzIG91CmNvbGV0w6JuZWFzLCByZXV0aWxpemHDp8OjbywgZWRpw6fDo28sIHByb2R1w6fDo28gZGUgbWF0ZXJpYWwgZGlkw6F0aWNvIGUgY3Vyc29zIG91IHF1YWxxdWVyIGZvcm1hIGRlCnV0aWxpemHDp8OjbyBuw6NvIGNvbWVyY2lhbDsKCigzKSBSRUNPTkhFQ0UgcXVlIGEgY2Vzc8OjbyBhcXVpIGVzcGVjaWZpY2FkYSBjb25jZWRlIMOgIEZJT0NSVVogLSBGVU5EQcOHw4NPIE9TV0FMRE8KQ1JVWiBvIGRpcmVpdG8gZGUgYXV0b3JpemFyIHF1YWxxdWVyIHBlc3NvYSDigJMgZsOtc2ljYSBvdSBqdXLDrWRpY2EsIHDDumJsaWNhIG91IHByaXZhZGEsIG5hY2lvbmFsIG91CmVzdHJhbmdlaXJhIOKAkyBhIGFjZXNzYXIgZSB1dGlsaXphciBhbXBsYW1lbnRlIGEgT0JSQSwgc2VtIGV4Y2x1c2l2aWRhZGUsIHBhcmEgcXVhaXNxdWVyCmZpbmFsaWRhZGVzIG7Do28gY29tZXJjaWFpczsKCig0KSBERUNMQVJBIHF1ZSBhIG9icmEgw6kgY3JpYcOnw6NvIG9yaWdpbmFsIGUgcXVlIMOpIG8gdGl0dWxhciBkb3MgZGlyZWl0b3MgYXF1aSBjZWRpZG9zIGUgYXV0b3JpemFkb3MsCnJlc3BvbnNhYmlsaXphbmRvLXNlIGludGVncmFsbWVudGUgcGVsbyBjb250ZcO6ZG8gZSBvdXRyb3MgZWxlbWVudG9zIHF1ZSBmYXplbSBwYXJ0ZSBkYSBPQlJBLAppbmNsdXNpdmUgb3MgZGlyZWl0b3MgZGUgdm96IGUgaW1hZ2VtIHZpbmN1bGFkb3Mgw6AgT0JSQSwgb2JyaWdhbmRvLXNlIGEgaW5kZW5pemFyIHRlcmNlaXJvcyBwb3IKZGFub3MsIGJlbSBjb21vIGluZGVuaXphciBlIHJlc3NhcmNpciBhIEZJT0NSVVogLSBGVU5EQcOHw4NPIE9TV0FMRE8gQ1JVWiBkZQpldmVudHVhaXMgZGVzcGVzYXMgcXVlIHZpZXJlbSBhIHN1cG9ydGFyLCBlbSByYXrDo28gZGUgcXVhbHF1ZXIgb2ZlbnNhIGEgZGlyZWl0b3MgYXV0b3JhaXMgb3UKZGlyZWl0b3MgZGUgdm96IG91IGltYWdlbSwgcHJpbmNpcGFsbWVudGUgbm8gcXVlIGRpeiByZXNwZWl0byBhIHBsw6FnaW8gZSB2aW9sYcOnw7VlcyBkZSBkaXJlaXRvczsKCig1KSBBRklSTUEgcXVlIGNvbmhlY2UgYSBQb2zDrXRpY2EgSW5zdGl0dWNpb25hbCBkZSBBY2Vzc28gQWJlcnRvIGRhIEZJT0NSVVogLSBGVU5EQcOHw4NPCk9TV0FMRE8gQ1JVWiBlIGFzIGRpcmV0cml6ZXMgcGFyYSBvIGZ1bmNpb25hbWVudG8gZG8gcmVwb3NpdMOzcmlvIGluc3RpdHVjaW9uYWwgQVJDQS4KCkEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVogcmVzZXJ2YQpleGNsdXNpdmFtZW50ZSBhbyBBVVRPUiBvcyBkaXJlaXRvcyBtb3JhaXMgZSBvcyB1c29zIGNvbWVyY2lhaXMgc29icmUgYXMgb2JyYXMgZGUgc3VhIGF1dG9yaWEKZS9vdSB0aXR1bGFyaWRhZGUsIHNlbmRvIG9zIHRlcmNlaXJvcyB1c3XDoXJpb3MgcmVzcG9uc8OhdmVpcyBwZWxhIGF0cmlidWnDp8OjbyBkZSBhdXRvcmlhIGUgbWFudXRlbsOnw6NvCmRhIGludGVncmlkYWRlIGRhIE9CUkEgZW0gcXVhbHF1ZXIgdXRpbGl6YcOnw6NvLgoKQSBQb2zDrXRpY2EgSW5zdGl0dWNpb25hbCBkZSBBY2Vzc28gQWJlcnRvIGRhIEZJT0NSVVogLSBGVU5EQcOHw4NPIE9TV0FMRE8gQ1JVWgpyZXNwZWl0YSBvcyBjb250cmF0b3MgZSBhY29yZG9zIHByZWV4aXN0ZW50ZXMgZG9zIEF1dG9yZXMgY29tIHRlcmNlaXJvcywgY2FiZW5kbyBhb3MgQXV0b3JlcwppbmZvcm1hciDDoCBJbnN0aXR1acOnw6NvIGFzIGNvbmRpw6fDtWVzIGUgb3V0cmFzIHJlc3RyacOnw7VlcyBpbXBvc3RhcyBwb3IgZXN0ZXMgaW5zdHJ1bWVudG9zLgo=Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352021-03-24T19:32:27Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults
title Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults
spellingShingle Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults
Menzies, Dick
Tuberculosis
Latent tuberculosis in adults
Rifampin
Isoniazid
title_short Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults
title_full Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults
title_fullStr Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults
title_full_unstemmed Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults
title_sort Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults
author Menzies, Dick
author_facet Menzies, Dick
Adjobimey, Menonli
Ruslami, Rovina
Trajman, Anete
Sow, Oumou
Kim, Heejin
Obeng Baah, Joseph
Marks, Guy B.
Long, Richard
Hoeppner, Vernon
Elwood, Kevin
Al-Jahdali, Hamdan
Gninafon, Martin
Apriani, Lika
Koesoemadinata, Raspati C.
Kritski, Afranio
Rolla, Valeria
Bah, Boubacar
Camara, Alioune
Boakye, Isaac
Cook, Victoria J.
Goldberg, Hazel
Valiquette, Chantal
Hornby, Karen
Dion, Marie-Josée
Li, Pei-Zhi
Hill, Philip C.
Schwartzman, Kevin
Benedetti, Andrea
author_role author
author2 Adjobimey, Menonli
Ruslami, Rovina
Trajman, Anete
Sow, Oumou
Kim, Heejin
Obeng Baah, Joseph
Marks, Guy B.
Long, Richard
Hoeppner, Vernon
Elwood, Kevin
Al-Jahdali, Hamdan
Gninafon, Martin
Apriani, Lika
Koesoemadinata, Raspati C.
Kritski, Afranio
Rolla, Valeria
Bah, Boubacar
Camara, Alioune
Boakye, Isaac
Cook, Victoria J.
Goldberg, Hazel
Valiquette, Chantal
Hornby, Karen
Dion, Marie-Josée
Li, Pei-Zhi
Hill, Philip C.
Schwartzman, Kevin
Benedetti, Andrea
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Menzies, Dick
Adjobimey, Menonli
Ruslami, Rovina
Trajman, Anete
Sow, Oumou
Kim, Heejin
Obeng Baah, Joseph
Marks, Guy B.
Long, Richard
Hoeppner, Vernon
Elwood, Kevin
Al-Jahdali, Hamdan
Gninafon, Martin
Apriani, Lika
Koesoemadinata, Raspati C.
Kritski, Afranio
Rolla, Valeria
Bah, Boubacar
Camara, Alioune
Boakye, Isaac
Cook, Victoria J.
Goldberg, Hazel
Valiquette, Chantal
Hornby, Karen
Dion, Marie-Josée
Li, Pei-Zhi
Hill, Philip C.
Schwartzman, Kevin
Benedetti, Andrea
dc.subject.en.pt_BR.fl_str_mv Tuberculosis
Latent tuberculosis in adults
Rifampin
Isoniazid
topic Tuberculosis
Latent tuberculosis in adults
Rifampin
Isoniazid
description Valéria Rolla. Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta a informação no documento. Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University Health Centre Research Institute (D.M., A.T., C.V., K.H., M.-J.D., P.Z.L., K.S., A.B.), and the Department of Epidemiology and Biostatistics (D.M., A.B.), McGill University, Montreal, the Faculty of Medicine and Dentistry, University of Alberta, Edmonton (R.L.), the Faculty of Medicine, University of Saskatchewan, Saskatoon (V.H.), and the BC Centre for Disease Control and the University of British Columbia, Vancouver (K.E., V.J.C.) — all in Canada; Centre National Hospitalier Universitaire de Pneumo-Phtisiologie, Cotonou, Benin (M.A., M.G.); the Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia (R.R., L.A., R.C.K.); State University of Rio de Janeiro (A.T.), Programa Academico de Tuberculose–Faculdade de Medicina, Universidade Federal do Rio de Janeiro–Rede TB (A.K.), and National Institute of Infectious Diseases Evandro Chagas (V.R.) — all in Rio de Janeiro; Service de Pneumophtisiologie, Hôpital National Ignace Deen, Université Gamal Abdel Nasser de Conakry, Conakry, Guinea (O.S., B.B., A.C.); Korean Institute of Tuberculosis, Seoul, South Korea (H.K.); Komfo Anokye Teaching Hospital, Kumasi, Ghana (J.O.B., I.B.); University of New South Wales (G.B.M.) and University of Sydney (H.G.), Sydney; Centre for International Health, University of Otago, Dunedin, New Zealand (P.C.H.); and the Department of Medicine, King Saud University, King Abdulaziz Medical City, Riyadh, Saudi Arabia (H.A.-J.).
publishDate 2018
dc.date.issued.fl_str_mv 2018
dc.date.accessioned.fl_str_mv 2019-07-01T14:39:44Z
dc.date.available.fl_str_mv 2019-07-01T14:39:44Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv MENZIES, D. et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. New England Journal of Medicine, v. 379, n. 5, p. 440-453, Aug. 2 2018.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/33753
dc.identifier.issn.pt_BR.fl_str_mv 0028-4793
dc.identifier.doi.none.fl_str_mv 10.1056/NEJMoa1714283
dc.identifier.eissn.none.fl_str_mv 1533-4406
identifier_str_mv MENZIES, D. et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. New England Journal of Medicine, v. 379, n. 5, p. 440-453, Aug. 2 2018.
0028-4793
10.1056/NEJMoa1714283
1533-4406
url https://www.arca.fiocruz.br/handle/icict/33753
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Massachusetts Medical Society
publisher.none.fl_str_mv Massachusetts Medical Society
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/33753/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/33753/2/ve_Menzies_D_etal_INI_2018.pdf
https://www.arca.fiocruz.br/bitstream/icict/33753/3/ve_Menzies_D_etal_INI_2018.pdf.txt
bitstream.checksum.fl_str_mv 79178e5f2a0eb066867a274556814938
d2a7963ffbac51b784b6286cad028272
a3bb7dfb0f4e60de467eb1e06af5df8f
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813009209905643520